Tumor profiling, also called genomic profiling or molecular profiling is an important facet of personalized medicine, by classifying tissue based on genetic profiles for the purposes of diagnosing or treating cancers, or predicting response to therapy.

Personalized medicine allows us to understand the genetic differences in our patients to determine their susceptibility to a particular disease or their response to a specific treatment. We can concentrate therapies on those who will benefit, sparing the expense and side effects for those who will not.

Instead of a “one-size-fits-all” approach where all patients with the same diagnosis receive the same treatment, we can use a personalized medicine approach and base the treatment strategy on the patient’s unique genetic profile.

Also through Sarah Cannon Cancer Institute, our access to early-phase clinical trials can leverage molecular profiling technologies. Other advantages include:

  • Oncology specific molecular profiling is offered across our HCA Midwest Health hospitals
  • Approved drugs are matched to individual patient profiles based on genomic testing, aiding in quick treatment decisions
  • Patient assistance or compassionate use applications are requested if there is a drug matched to an indication that is currently in clinical trials
  • HCA Midwest Health is conducting trials with pharmaceutical partners that have a primary focus in genomic profiling connected to appropriate drug planning and delivery to our patients